TRIESENCE (Triamcinolone Acetonide) Patent Expiration, LOE Window & CMS Spending

TRIESENCE (Triamcinolone Acetonide) by Harrow Eye: FDA Orange Book core substance LOE 2029-12-17, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHarrow Eye
FDA Application & PathwayN022048 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2029-12-17
Last Listed Patent or Exclusivity Date2029-12-17
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 527.6% 2-yr change)